Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc (NASDAQ: ALXN) | World Leader in Treatments for Patients with Devastating and Rare Diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
$39.0b (Public information from Dec 2020)
Share price
€15.55 ALXN
Boston Massachusetts (HQ)
Financials
Estimates*
USD | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|---|
Revenues | - | 3.6b | 4.1b | 5.0b | 6.1b | 6.6b | 7.2b |
% growth | - | - | 16 % | 21 % | 22 % | 10 % | 8 % |
EBITDA | - | 2.1b | 2.6b | 3.2b | 3.7b | 4.0b | 4.0b |
% EBITDA margin | - | 59 % | 63 % | 63 % | 61 % | 60 % | 56 % |
Profit | - | 443m | 77.0m | 2.4b | 603m | 2.5b | 2.8b |
% profit margin | - | 12 % | 2 % | 48 % | 10 % | 38 % | 38 % |
R&D budget | 790m | 805m | 702m | 868m | - | - | - |
R&D % of revenue | - | 23 % | 17 % | 17 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Early VC | ||
N/A | N/A | IPO | |
N/A | RSD3.5m | Seed | |
$39.0b Valuation: $39.0b 7.8x EV/LTM Revenues 12.3x EV/LTM EBITDA | Acquisition | ||
Total Funding | $38.5k |
Related Content
Recent News about Alexion Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Alexion Pharmaceuticals
Editexited
ACQUISITION by Alexion Pharmaceuticals May 2015
ACQUISITION by Alexion Pharmaceuticals Jan 2011
ACQUISITION by Alexion Pharmaceuticals Dec 2011
ACQUISITION by Alexion Pharmaceuticals Oct 2019
ACQUISITION by Alexion Pharmaceuticals May 2020
ACQUISITION by Alexion Pharmaceuticals Apr 2018
ACQUISITION by Alexion Pharmaceuticals Oct 2022